Keywords
How to Cite
Abstract
Research during the past decade has shown that epigenetic events have a key role in carcinogenesis and tumour progression. Histone deacetylase inhibitors (HDACi) comprise structurally diverse compounds that are a group of targeted epigenetic anticancer agents. Here we explored the in vitro efficacy of HDACi such as sodium butyrate (BuNa), valproic acid (VaNa) and several novel HDAC inhibitors for the treatment of cancer. Both BuNa and VaNa inhibited cancer cell proliferation in a time—and dose-dependent fashion. In the present study we demonstrated the significant effect of two novel HDACi, Adipo or BuNHOH, able to induce apoptosis of cancer cells, but not of normal line. Since HDAC inhibitors have been proposed as radio — or chemosensitizers in cancer therapy, we have studied the radiosensitizing effect of sodium butyrate on cancer cells. The combination of BuNa and radiation significantly inhibited tumor cell growth. Besides, combining Cisplatin or Gemzar with HDAC inhibitors results in synergistic antiproliferative activity that could be therapeutically exploited. These results suggest that HDACi acts as an antitumor agent and that combining HDAC inhibitors with radio or—chemotherapeutic strategy may provide a novel chemotherapeutic treatment of cancers insensitive to traditional antitumor agents.References
Чехун В.Ф. Эпигенетика рака // Онкология. -2008. -т. 10. - № 3. - С. 301-302
Штам Т.А., Виноградская Г.Р., Волницкий А.В.и др. Эпигенетическая регуляция функционирования некоторых онкогенови возможности ее практического использования // Клинико-лабораторный консилиум -2012. Т. 1(41). C. 53-58.
Ai T., Cui H., Chen L. Multi-targeted histone deacetylase inhibitors in cancer therapy // Curr Med Chem. 2012. Vol. 19(4). P. 475-487.
Bangert A., Hcker S., Cristofanon S. et al. Chemosensitization of glioblastoma cells by the histone deacetylase inhibitor MS275 // Anticancer Drugs 2011. Vol. 22(6). P. 494-499.
Carew J.S., Giles F.J., Nawrocki S.T. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy // Cancer Lett. 2008. Vol. 269(1). P. 7-17.
Entin-Meer M., Yang X., VandenBerg S.R. et al. In vivo efficacy ofa novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas // Neuro Oncol. 2007. Vol. 9(2). P. 82-88.
Entin-Meer M., Rephaeli A., Yang X. et al. Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas // Mol Cancer Ther. 2005. Vol. 4(12). P.1952-1961.
Gryder B.E., Sodji Q.H., Oyelere A.K. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed // Future Med Chem. -2012. Vol. 4(4). P. 505-524.
Hrzenjak A., Moinfar F., Kremser M.L. et al. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo // Molecular Cancer -2010. Vol. 9. P. 49.
Kanwal R., Gupta S. Epigenetic modifications in cancer // Clin Genet. 2012. Vol. 81(4). P. 303-311.
Kawano T., Akiyama M., Agawa-Ohta M. et al. Histone deacetylase inhibitors valproic acid and depsipeptide sensitize retinoblastoma cells to radiotherapy by increasing H2AX phosphorylation and p53 acetylation-phosphorylation // Int J Oncol. -2010. Vol. 37(4). P.787-795.
Kim E. H., Kim H. S., Kim S. U. et al. Sodium butyrate sensitizes human glioma cells to TRAIL-mediated apoptosis through inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP // Oncogene 2005. Vol. 24(46). P. 6877-6889.
Kouzarides T. Chromatin modifications and their function // Cell. 2007. Vol. 128(4). P. 693-705.
Lee J. H., Choy M L., Ngo L. et al. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair // Proc Natl Acad Sci U S A. -2010. Vol. 107(33). P. 14639-14644.
Masoudi A., Elopre M., Amini E. et al. Influence of valproic acid on outcome of high-grade gliomas in children // Anticancer Res. -2008. Vol. 28(4C). P. 2437-2442.
Pan H., Cao J., Xu W. Selective histone deacetylase inhibitors // Anticancer Agents Med Chem. -2012. Vol. 12(3). P. 247-257.
Shankar S., Srivastava R.K. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis // Adv Exp Med Biol. -2008. Vol. 615. P. 261-298.
Xu X., Jiang Z., Yin P. et al. Role for Class I histone deacetylases in multidrug resistance. // Exp Cell Res. 2012. Vol. 318(3). P. 177-186.
Yoo C.B., Jones P.A. Epigenetic therapy of cancer: past, present and future // Nat Rev Drug Discov. -2006. Vol. 5(1). P. 37-50.
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...